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Disclosure Statement
• Dr. Franson has no financial investments and 
receives no funding from any of the private 
companies talked about in this presentation
• Dr. Franson will be discussing unapproved drugs 
and unapproved uses for drugs.
• This presentation is based on Borgelt LM, Franson KL, Nussbaum 
Am, Wang GS.  “The Pharmacologic and Clinical Effects of 
Medical Cannabis” Pharmacotherapy 2013;33(2):195–209
1) explain what cannabis does to the human body 
with a focus on THC & CBD (pharmacology) 
2) compare the various routes of cannabis 
administration and how the human body 
manages the drug (pharmacokinetics)
3) evaluate new Colorado Amendment 64 
legislation considering what is known about 
clinical pharmacology
At the end of the session, participants 
will be able to:
Pharmacology
Cannabis (sativa, indica, ruderalis)
Plant-derived cannabinoids 
– ∆9 -tetrahydrocannabinol (9) - THC
– ∆9 -tetrahydrocannabivarin - THCV








Br J Pharmacology 2006;147:S163-171
Cannabinoid/CB receptor interactions
Cannabinoid receptor active ligands
Normal neurotransmission
Regulatory effects of cannabinoids
Pertwee RG, Br J Pharm, 2008
Normal neurotransmission in a network
Regulatory effects of cannabinoids
Pertwee RG, Br J Pharm, 2008
Distribution of CB1 & CB2 receptors
CB2  




(possible role in 
Alzheimer’s?)
CB1
DA:  reward and 
motivation










– Long term gain
– Thoughtful 
behavior
Brain development in adolescence
http://erichengelhardt.net/neuro-facts.html accessed 5/28/2013
Amendment 64 prohibits the sale 
and use of cannabis products by 
those younger than 21 years.  Why?
The adolescent brain is still developing.  
There is concern that the reward pathways 
and feedback loops may be altered if 
cannabis is used by those with still 
developing brains.   
Non-cannabinoid targets linked to 
cannabis 
• Other G-protein receptors:  GPR55, GPR55940, etc
• G-protein-coupled receptors:  noncompetitive inhibitor at 
μ- and δ-opioid receptors, NE, DA, 5-HT
• Ligand-gated ion channels: antagonism at 5-HT3, 
nicotinic, and enhance activation of glycine receptors
• Transient receptor potential channels (TRPVs):  bind 
and activate TRPV1 similar to capsaicin, also CB1 
receptors are located near TRPV1
• Ion channels:  inhibition of Ca, K, Na channels by non-
competitive antagonism
• Peroxisome Proliferator-Activated Receptors:  PPARα
and PPARγ are activated 
Pertwee RG, Pharma Rev 2010
What is in medical cannabis?
www.fullspectrumlabs.com Accessed 07/18/2011
To review:
What does THC do to the human body?
– it is a partial agonist for the CB1 receptor
– CB1 receptors regulate the release of other 
neurotransmitters
– CB1 receptors are primarily located in the brain; 
effecting thinking, memory, appetite, reward and 
movements
– It is the most psychoactive substance in cannabis
What does CBD do to the human body? 
Pharmacokinetics
Pharmacokinetic profile of THC
Smoking: 
• Bioavailability: 10-25%
50% of the THC content is 
delivered into smoke
50% of smoke is exhaled again 
60% of inhaled smoke may be 
metabolized in the lung 
• Peak concentrations are high and 
reached within minutes
• t½ distribution 0.5 hr, 
t½ for elimination 30 hr
Agurell S, 1986; Strougo A, 2005
Vaporization of medical cannabis
• Cannabinoids 




• Lower % of noxious 
chemicals
http://www.volcanovaporizer.com/products-page/complete-sets/ Accessed 08/31/2012
Pharmacokinetic profile of THC
Oral:
•Bioavailability: 5-20% 
Often considered 1/3 that of 
smoked due to gastric 
degradation and extensive 
first-pass effects
High intra-patient variability!
•Multiple peak concentrations 
are low and reached in 1-3 hr
•t½ absorption 0.8 hr, 
t½ distribution 3.8 hr
t½ for elimination 25 hr
Agurell S, 1984; Ohlsson A, 1980
THC is the most psychoactive 
component of cannabis
Typical “effective” dosing of THC
• Low dose < 7 mg
• Medium dose = 7 – 18 mg
• High dose > 18 mg 
There is a known tolerance to THC via down 
regulation of CB1 receptors
High probability of tolerance with chronic use, 
and low with intermittent 
Zuurman L, Brit J Clin Pharm 2009
CO HB 13-1317 labeling of product
• A net weight statement;
• THC potency and the potency of such other 
cannabinoids or other chemicals, including but 
not limited to CBD, 
• A serving size for edible retail marijuana 
products that does not contain more than ten 
milligrams of active THC, …, and limitations on 
the total amount of active THC in a package that 
is no more than one hundred milligrams of active 
THC;
How much should a person use to 
get 25 mg of THC?  
• 20% THC
• Net weight 1/8 oz or 
3.5 gm
• Single serving 50 mg
http://onehumanbeing.com/the_mmj_project/2009/03/granddaddy-purple-at-cclb/
http://bothcollective.com/page/6/?app-download=windowsphone
The pharmacodynamics of THC
• Evaluated 165 studies to determine 
consistently found PD effects 
– Elevation in heart rate (average >19 bpm)
– Increase in subjective feeling high
– Decrease in subjective alertness
– Increase in motor instability (body sway)
Zuurman L, Brit J Clin Pharm 2009
PK/PD modeling of THC
• Subjects given 
increasing 
doses (2, 4, 6, 
8 mg) of THC 
via Volcano 








Time (hr)Adapted from Zuurman L, Brit J Clin Pharm 2009
PK/PD modeling of THC
Heart rate (bpm) VAS feeling high (U) VAS alertness (mm) 
Time (hrs) Time (hrs) Time (hrs)
heart rate feeling high alertness
Adapted from Zuurman L, Brit J Clin Pharm 2009
A man in a MVA is found to have a 
blood THC level of 10 ng/ml. House 
Bill 1325 set THC limit at 5 ng/ml
1. The man did not reach the level of impairment
2. The man was above the known level of 
impairment 
3. The level of presumptive impairment is not 
known
4. It is not known if the man was impaired with this 
concentration
Population response to medical 
cannabis
• Hormones:  
– Males: decreased LH, FSH, prolactin, and GH levels
– Females: more sensitive to THC effects (pain, 
behavior, reward) with higher estrogen levels
• Tobacco:  greater increases in HR and carbon 
monoxide, despite lower THC concentrations 
• MDMA:  synergistic impairment in working memory
• CV patients: ↑HR and ↓HRV with cannabis use






Wang GS JAMA Pediatrics, 2013 http://opiophilia.blogspot.com/2013_04_01_archive.html
To review:
What does the human body do to THC?
– Smoking THC mimics IV, but with 10-25% 
bioavailability, quick effect  easy to titrate
– Ingesting THC, 1/3 bioavailability, high variability 
and delayed effect  increased toxicities
– Medium dose ≈ 10mg, giving rise to ↑HR, ↑high,
↓alertness, ↓stability, but tolerance quickly 
develops
– Acute THC ingestions are relatively safe
Wrap-up from today’s session
1) Explained the pharmacology of THC & CBD 
2) Compare the pharmacokinetics with various 
forms of cannabis 
3) Examined new Colorado legislation considering 
what is known about clinical pharmacology
4) Questions?
